[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

Abstract excerpt

Approximately 90 % of gastrointestinal tumors (GISTs) harbor an activating mutation in KIT or PDGFR alpha oncogene known to confer imatinib sensitivity. Imatinib is a tyrosine kinase inhibitor of KIT and PDGFRs that yields a 6-months progression-free survival (PFS) rate of 80 % in patients with advanced GISTs. Several studies have shown that response to imatinib in GIST patients mainly depends on the mutational...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Phenylurea Compounds
• Share to Phthalazines
• Share to Benzenesulfonates